| Pain relief into practice: rhetoric without reform |
| KM Foley |
|
JCO Sep 1 1995: 2149–2151.
[PDF]
|
 |
| Cost-effectiveness analysis: sleeping with an enemy or a friend? |
| SC Gulati and JD Bitran |
|
JCO Sep 1 1995: 2152–2154.
[PDF]
|
|
| Suramin and prostate cancer: where do we go from here? |
| JW Clark and BA Chabner |
|
JCO Sep 1 1995: 2155–2157.
[PDF]
|
|
|
An institutional commitment to pain management |
| |
BR Ferrell, GE Dean, M Grant, and P Coluzzi |
| |
JCO Sep 1 1995: 2158–2165.
[Abstract]
[PDF]
|
|
|
Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer |
| |
TJ Smith, BE Hillner, DM Neighbors, PA McSorley, and T Le Chevalier |
| |
JCO Sep 1 1995: 2166–2173.
[Abstract]
[PDF]
|
|
|
Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer |
| |
MA Eisenberger, VJ Sinibaldi, LM Reyno, R Sridhara, DI Jodrell, EG Zuhowski, KH Tkaczuk, MH Lowitt, RK Hemady, and SC Jacobs |
| |
JCO Sep 1 1995: 2174–2186.
[Abstract]
[PDF]
|
|
|
Development and validation of a pharmacokinetically based fixed dosing scheme for suramin |
| |
LM Reyno, MJ Egorin, MA Eisenberger, VJ Sinibaldi, EG Zuhowski, and R Sridhara |
| |
JCO Sep 1 1995: 2187–2195.
[Abstract]
[PDF]
|
|
|
Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer [published erratum appears in J Clin Oncol 1996 Sep;14(9):2623-4] |
| |
K Kobayashi, EE Vokes, NJ Vogelzang, L Janish, B Soliven, and MJ Ratain |
| |
JCO Sep 1 1995: 2196–2207.
[Abstract]
[PDF]
|
|
|
Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer |
| |
WK Kelly, T Curley, C Leibretz, A Dnistrian, M Schwartz, and HI Scher |
| |
JCO Sep 1 1995: 2208–2213.
[Abstract]
[PDF]
|
|
|
Suramin and hydrocortisone: determining drug efficacy in androgen- independent prostate cancer |
| |
WK Kelly, HI Scher, M Mazumdar, D Pfister, T Curley, C Leibertz, L Cohen, V Vlamis, A Dnistrian, and M Schwartz |
| |
JCO Sep 1 1995: 2214–2222.
[Abstract]
[PDF]
|
|
|
Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin |
| |
RJ Bitton, WD Figg, DJ Venzon, MC Dalakas, C Bowden, D Headlee, E Reed, CE Myers, and MR Cooper |
| |
JCO Sep 1 1995: 2223–2229.
[Abstract]
[PDF]
|
|
|
Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study |
| |
RC Lilenbaum, MJ Ratain, AA Miller, JB Hargis, DR Hollis, GL Rosner, SM O'Brien, L Brewster, MR Green, and RL Schilsky |
| |
JCO Sep 1 1995: 2230–2237.
[Abstract]
[PDF]
|
|
|
Phase I trial of carboplatin and infusional cyclosporin in advanced malignancy |
| |
RJ Morgan, Jr, K Margolin, J Raschko, S Akman, L Leong, G Somlo, K Scanlon, C Ahn, M Carroll, and JH Doroshow |
| |
JCO Sep 1 1995: 2238–2246.
[Abstract]
[PDF]
|
|
|
Preirradiation chemotherapy with carboplatin and etoposide in newly diagnosed embryonal pediatric CNS tumors |
| |
RL Heideman, EH Kovnar, SJ Kellie, EC Douglass, AJ Gajjar, AW Walter, JA Langston, JJ Jenkins, Y Li, and C Greenwald |
| |
JCO Sep 1 1995: 2247–2254.
[Abstract]
[PDF]
|
|
|
Stage I testicular seminoma: results of adjuvant irradiation and surveillance |
| |
P Warde, MK Gospodarowicz, T Panzarella, CN Catton, JF Sturgeon, M Moore, P Goodman, and MA Jewett |
| |
JCO Sep 1 1995: 2255–2262.
[Abstract]
[PDF]
|
|
|
Biphasic patterns of memory deficits following moderate-dose partial- brain irradiation: neuropsychologic outcome and proposed mechanisms |
| |
C Armstrong, J Ruffer, B Corn, K DeVries, and J Mollman |
| |
JCO Sep 1 1995: 2263–2271.
[Abstract]
[PDF]
|
|
|
Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial |
| |
CJ Logothetis, LD Finn, T Smith, RG Kilbourn, JA Ellerhorst, AA Zukiwski, A Sella, SM Tu, and RJ Amato |
| |
JCO Sep 1 1995: 2272–2277.
[Abstract]
[PDF]
|
|
|
Evaluation of reproductive capacity in germ cell tumor patients following treatment with cisplatin, etoposide, and bleomycin |
| |
WT Stephenson, SM Poirier, L Rubin, and LH Einhorn |
| |
JCO Sep 1 1995: 2278–2280.
[Abstract]
[PDF]
|
|
|
Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu |
| |
FH Valone, PA Kaufman, PM Guyre, LD Lewis, V Memoli, Y Deo, R Graziano, JL Fisher, L Meyer, and M Mrozek-Orlowski |
| |
JCO Sep 1 1995: 2281–2292.
[Abstract]
[PDF]
|
|
|
p53 mutations in benign breast tissue |
| |
R Millikan, B Hulka, A Thor, Y Zhang, S Edgerton, X Zhang, H Pei, M He, L Wold, and LJ Melton |
| |
JCO Sep 1 1995: 2293–2300.
[Abstract]
[PDF]
|
|
|
Modulation of O6-alkylguanine alkyltransferase-directed DNA repair in metastatic colon cancers |
| |
JK Willson, JR Haaga, JE Trey, TA Stellato, NH Gordon, and SL Gerson |
| |
JCO Sep 1 1995: 2301–2308.
[Abstract]
[PDF]
|
|
|
Lymph node staging standards in gastric cancer |
| |
AM Bunt, PC Hogendoorn, CJ van de Velde, JA Bruijn, and J Hermans |
| |
JCO Sep 1 1995: 2309–2316.
[Abstract]
[PDF]
|
|
|
Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer |
| |
M Hill, A Norman, D Cunningham, M Findlay, M Watson, V Nicolson, A Webb, G Middleton, F Ahmed, and T Hickish |
| |
JCO Sep 1 1995: 2317–2323.
[Abstract]
[PDF]
|
|
|
Controlled clinical trial of interferon-gamma as postoperative surgical adjuvant therapy for colon cancer |
| |
M Wiesenfeld, MJ O'Connell, HS Wieand, NJ Gonchoroff, JH Donohue, RJ Fitzgibbons, Jr, JE Krook, JA Mailliard, JB Gerstner, and R Pazdur |
| |
JCO Sep 1 1995: 2324–2329.
[Abstract]
[PDF]
|
|
|
Surgical treatment of spinal cord compression from epidural metastasis |
| |
N Sundaresan, VP Sachdev, JF Holland, F Moore, M Sung, PA Paciucci, LT Wu, K Kelligher, and L Hough |
| |
JCO Sep 1 1995: 2330–2335.
[Abstract]
[PDF]
|
|
|
Role of surgical resection in pelvic Ewing's sarcoma |
| |
SP Scully, HT Temple, RJ O'Keefe, MT Scarborough, HJ Mankin, and MC Gebhardt |
| |
JCO Sep 1 1995: 2336–2341.
[Abstract]
[PDF]
|
|
|
Bone marrow-sparing and prevention of alopecia by AS101 in non-small- cell lung cancer patients treated with carboplatin and etoposide |
| |
B Sredni, M Albeck, T Tichler, A Shani, J Shapira, I Bruderman, R Catane, B Kaufman, and Y Kalechman |
| |
JCO Sep 1 1995: 2342–2353.
[Abstract]
[PDF]
|
|
|
Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group |
| |
GP Browman, D Bergsagel, D Sicheri, S O'Reilly, KS Wilson, S Rubin, A Belch, C Shustik, R Barr, and I Walker |
| |
JCO Sep 1 1995: 2354–2360.
[Abstract]
[PDF]
|
|
|
Prognostic value of size of lymph node metastases in patients with cutaneous melanoma |
| |
AC Buzaid, LA Tinoco, D Jendiroba, ZN Tu, JJ Lee, SS Legha, MI Ross, CM Balch, and RS Benjamin |
| |
JCO Sep 1 1995: 2361–2368.
[Abstract]
[PDF]
|
|
|
Patient participation in clinical decision-making for treatment of T3 laryngeal cancer: a comparison of state and process utilities |
| |
J van der Donk, PC Levendag, AJ Kuijpers, FH Roest, JD Habbema, CA Meeuwis, and PI Schmitz |
| |
JCO Sep 1 1995: 2369–2378.
[Abstract]
[PDF]
|
|
|
Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease |
| |
JA Radford, D Crowther, AZ Rohatiner, WD Ryder, RK Gupta, A Oza, DP Deakin, S Arnott, PM Wilkinson, and RD James |
| |
JCO Sep 1 1995: 2379–2385.
[Abstract]
[PDF]
|
|
|
Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma |
| |
RM Meyer, GP Browman, ML Samosh, AM Benger, D Bryant-Lukosius, WE Wilson, GL Frank, BF Leber, MS Sternbach, and GA Foster |
| |
JCO Sep 1 1995: 2386–2393.
[Abstract]
[PDF]
|
|
|
Survival of patients with resistant Hodgkin's disease after polyclonal yttrium 90-labeled antiferritin treatment |
| |
JM Herpst, JL Klein, PK Leichner, SM Quadri, and HM Vriesendorp |
| |
JCO Sep 1 1995: 2394–2400.
[Abstract]
[PDF]
|
|
|
Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia |
| |
S Sacchi, H Kantarjian, S O'Brien, PR Cohen, S Pierce, and M Talpaz |
| |
JCO Sep 1 1995: 2401–2407.
[Abstract]
[PDF]
|
|
|
Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo |
| |
RM Navari, S Madajewicz, N Anderson, NS Tchekmedyian, W Whaley, H Garewal, TM Beck, AY Chang, B Greenberg, and KC Caldwell |
| |
JCO Sep 1 1995: 2408–2416.
[Abstract]
[PDF]
|
|
|
Persistence of efficacy of three antiemetic regimens and prognostic factors in patients undergoing moderately emetogenic chemotherapy. Italian Group for Antiemetic Research |
| |
|
| |
JCO Sep 1 1995: 2417–2426.
[Abstract]
[PDF]
|
|
|
Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study |
| |
AG Robertson, NS Reed, and SH Ralston |
| |
JCO Sep 1 1995: 2427–2430.
[Abstract]
[PDF]
|
|
|
Infectious and immunosuppressive complications of purine analog therapy |
| |
BD Cheson |
| |
JCO Sep 1 1995: 2431–2448.
[Abstract]
[PDF]
|
|
|
Breaking bad news: consensus guidelines for medical practitioners |
| |
A Girgis and RW Sanson-Fisher |
| |
JCO Sep 1 1995: 2449–2456.
[Abstract]
[PDF]
|
|
|
Free-riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials |
| |
CL Bennett, TJ Smith, SL George, BE Hillner, S Fleishman, and HB Niell |
| |
JCO Sep 1 1995: 2457–2463.
[Abstract]
[PDF]
|
|
|
Ethical considerations in oncology: balancing the interests of patients, oncologists, and society |
| |
TJ Smith and JN Bodurtha |
| |
JCO Sep 1 1995: 2464–2470.
[Abstract]
[PDF]
|
|
| It is time to stratify with prognostic factors for hepatic metastases |
| NJ Petrelli |
|
JCO Sep 1 1995: 2471–2472.
[PDF]
|
|
| Perceptions of cancer patients and their physicians involved in phase I clinical trials |
| PL Weiden and JW Appelbaum |
|
JCO Sep 1 1995: 2472a.
[PDF]
|
|
| Remarks on "molecular markers and stem-cell transplants: are they made for each other?" |
| F Cabanillas |
|
JCO Sep 1 1995: 2472b–2473.
[PDF]
|
|
| Benefits of epoetin alfa therapy in anemic cancer patients receiving chemotherapy |
| DH Henry and RI Abels |
|
JCO Sep 1 1995: 2473–2474.
[PDF]
|
|
| Loss of activity of Erwinia asparaginase on repeat applications |
| J Boos, U Nowak-Gottl, H Jurgens, G Fleischhack, and U Bode |
|
JCO Sep 1 1995: 2474–2475.
[PDF]
|
|
| Response and control: lessons from oligodendroglioma |
| JG Cairncross and EA Eisenhauer |
|
JCO Sep 1 1995: 2475–2476.
[PDF]
|
|
| Response of meningeal Waldenstrom's macroglobulinemia to 2- chlorodeoxyadenosine |
| AI Richards |
|
JCO Sep 1 1995: 2476.
[PDF]
|
|
